JP2017538412A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538412A5
JP2017538412A5 JP2017530686A JP2017530686A JP2017538412A5 JP 2017538412 A5 JP2017538412 A5 JP 2017538412A5 JP 2017530686 A JP2017530686 A JP 2017530686A JP 2017530686 A JP2017530686 A JP 2017530686A JP 2017538412 A5 JP2017538412 A5 JP 2017538412A5
Authority
JP
Japan
Prior art keywords
seq
binding member
variant
amino acid
functional fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017530686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/059562 external-priority patent/WO2016092524A1/en
Publication of JP2017538412A publication Critical patent/JP2017538412A/ja
Publication of JP2017538412A5 publication Critical patent/JP2017538412A5/ja
Pending legal-status Critical Current

Links

JP2017530686A 2014-12-11 2015-12-11 ヒトc−mafに対する結合メンバー Pending JP2017538412A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090599P 2014-12-11 2014-12-11
US62/090,599 2014-12-11
PCT/IB2015/059562 WO2016092524A1 (en) 2014-12-11 2015-12-11 Binding members for human c-maf

Publications (2)

Publication Number Publication Date
JP2017538412A JP2017538412A (ja) 2017-12-28
JP2017538412A5 true JP2017538412A5 (cg-RX-API-DMAC7.html) 2019-01-24

Family

ID=55024191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017530686A Pending JP2017538412A (ja) 2014-12-11 2015-12-11 ヒトc−mafに対する結合メンバー

Country Status (10)

Country Link
US (1) US10793642B2 (cg-RX-API-DMAC7.html)
EP (1) EP3229909B1 (cg-RX-API-DMAC7.html)
JP (1) JP2017538412A (cg-RX-API-DMAC7.html)
KR (1) KR20170093182A (cg-RX-API-DMAC7.html)
CN (1) CN107001480B (cg-RX-API-DMAC7.html)
AU (1) AU2015358868A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017012515A2 (cg-RX-API-DMAC7.html)
CA (1) CA2967224C (cg-RX-API-DMAC7.html)
MX (1) MX2017007381A (cg-RX-API-DMAC7.html)
WO (1) WO2016092524A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047398B2 (en) 2010-10-06 2018-08-14 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
BR112015008255B1 (pt) 2012-10-12 2023-02-28 Inbiomotion S.L Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte
BR112015023510A2 (pt) 2013-03-15 2017-10-10 Fundacio Inst De Recerca Biomedica Irb Barcelona método para o diagnóstico, prognóstico e tratamento de câncer metastático
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
DK3901283T3 (da) 2016-05-25 2025-09-15 Inbiomotion Sl Terapeutisk behandling af brystkræft baseret på c-maf-status
MX2020005182A (es) 2017-11-22 2020-08-17 Inbiomotion Sl Tratamiento terapeutico del cancer de mama basado en el estado del c-maf.

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5185243A (en) 1988-08-25 1993-02-09 Syntex (U.S.A.) Inc. Method for detection of specific nucleic acid sequences
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
GB9509957D0 (en) 1995-05-17 1995-07-12 Khalil Nasreen Post-translational activation of tgf-›1 involving the tsp-1 receptor cd36
US5814468A (en) 1996-03-27 1998-09-29 Coulter International Corp. Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution
US5958671A (en) 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US6017729A (en) 1996-12-23 2000-01-25 Immunex Corporation Receptor activator of NF-κB
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) * 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
EP1178958B1 (en) 1999-03-15 2004-02-18 Axys Pharmaceuticals, Inc. N-cyanomethyl amides as protease inhibitors
EP1248612B1 (en) 2000-01-06 2008-02-27 Merck Frosst Canada Ltd. Novel compounds and compositions as protease inhibitors
JP2004505611A (ja) 2000-04-03 2004-02-26 コリクサ コーポレイション 乳癌の検出およびモニタリングのための方法、組成物、およびキット
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
NO345566B1 (no) 2001-06-26 2021-04-19 Amgen Inc OPGL bindende antistoff, farmasøytisk sammensetning samt anvendelse derav
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
US7741077B2 (en) 2001-12-22 2010-06-22 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
WO2005046731A1 (en) 2003-10-17 2005-05-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
US20090048117A1 (en) 2003-12-18 2009-02-19 President And Fellows Of Harvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
JP5457673B2 (ja) 2005-09-20 2014-04-02 ベリデックス・リミテッド・ライアビリティ・カンパニー ユニーク配列のdnaプローブを作製するための方法および組成物、dnaプローブの標識、ならびにこれらプローブの使用
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8785150B2 (en) 2006-06-30 2014-07-22 University Of Southern California Quantifiable internal reference standards for immunohistochemistry and uses thereof
WO2008086800A2 (en) 2007-01-15 2008-07-24 Aarhus Universitet Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
CA2676791A1 (en) 2007-02-16 2008-11-06 Pacific Arrow Limited Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
EP2152747B1 (en) 2007-05-24 2018-01-03 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
RU2011101378A (ru) 2008-06-16 2012-07-27 Сайвидон Дайагностикс Гмбх (De) Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии
EP2412825B8 (en) 2009-03-24 2018-01-10 Riken Leukemia stem cell markers
WO2011039734A2 (en) 2009-10-02 2011-04-07 Enzo Medico Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
US10047398B2 (en) 2010-10-06 2018-08-14 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
EP2671076A4 (en) 2011-02-04 2016-11-16 Bioarray Genetics Inc METHODS OF USING GENE EXPRESSION SIGNATURES FOR SELECTING A TREATMENT METHOD, PREDICTING PROGNOSIS, SURVIVAL, AND / OR PREDICTING A RESPONSE TO TREATMENT
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
BR112015008255B1 (pt) 2012-10-12 2023-02-28 Inbiomotion S.L Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
EP2971113B1 (en) 2013-03-15 2020-08-12 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the prognosis and treatment of cancer metastasis
BR112015023510A2 (pt) 2013-03-15 2017-10-10 Fundacio Inst De Recerca Biomedica Irb Barcelona método para o diagnóstico, prognóstico e tratamento de câncer metastático
KR20160061424A (ko) 2013-10-09 2016-05-31 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 유방암으로부터 기원하는 골의 전이성 암의 예후 및 치료 방법
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
DK3901283T3 (da) 2016-05-25 2025-09-15 Inbiomotion Sl Terapeutisk behandling af brystkræft baseret på c-maf-status
MX2020005182A (es) 2017-11-22 2020-08-17 Inbiomotion Sl Tratamiento terapeutico del cancer de mama basado en el estado del c-maf.

Similar Documents

Publication Publication Date Title
JP2017538412A5 (cg-RX-API-DMAC7.html)
JP2012526530A5 (cg-RX-API-DMAC7.html)
JP2016536330A5 (cg-RX-API-DMAC7.html)
JP2020522261A5 (cg-RX-API-DMAC7.html)
JP2018121657A5 (cg-RX-API-DMAC7.html)
JP2016029056A5 (cg-RX-API-DMAC7.html)
JP2016533395A5 (cg-RX-API-DMAC7.html)
JP2019513784A5 (cg-RX-API-DMAC7.html)
NL300919I2 (nl) Brodalumab
JP2012012402A5 (cg-RX-API-DMAC7.html)
JP2014506132A5 (cg-RX-API-DMAC7.html)
JP2013506428A5 (cg-RX-API-DMAC7.html)
RU2015147287A (ru) Гуманизированные антитела против axl
JP2017532005A5 (cg-RX-API-DMAC7.html)
JP2018516853A5 (cg-RX-API-DMAC7.html)
AR084210A1 (es) PROTEINAS DE UNION AL TNF-a
JP2016500655A5 (cg-RX-API-DMAC7.html)
JP2013544756A5 (cg-RX-API-DMAC7.html)
JP2008529489A5 (cg-RX-API-DMAC7.html)
JP2010523592A5 (cg-RX-API-DMAC7.html)
JP2012523848A5 (cg-RX-API-DMAC7.html)
WO2012145469A8 (en) Human monoclonal antibodies specific for glypican-3 and use thereof
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
JP2013165711A5 (cg-RX-API-DMAC7.html)
AR077594A1 (es) Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)